Brief: Prescient Therapeutics Says Us FDA Grants Orphan Drug Designation To Ptx-100 For Ptcl
15/07/2022 02:20
July 15 (Reuters) - Prescient Therapeutics PTX.AX :
* US FDA GRANTS ORPHAN DRUG DESIGNATION TO PTX-100 FOR
PTCL-PTX.AX
Source text for Eikon: ID:nASXbtg9wg
Further company coverage: PTX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prescient Therapeutics
See all newsAustralia's Prescient Therapeutics falls on discounted share placement
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial